Identification

Name
Candicidin
Accession Number
DB01152  (APRD00843)
Type
Small Molecule
Groups
Withdrawn
Description

Candicidin is an antibiotic obtained from a streptomyces (Streptomyces griseus) and active against some fungi of the genus Candida (C. albicans). Candicidin is administered intravaginally in the treatment of vulvovaginal candidiasis.

Synonyms
  • Candicidina
  • Candicidine
  • Candicidinum
  • Candizidin
International/Other Brands
Candicidin A / Candicidin D / FR-008-III / Prostatin
Categories
UNII
48N2IYJ202
CAS number
1403-17-4
Weight
Not Available
Chemical Formula
Not Available
InChI Key
Not Available
InChI
Not Available
IUPAC Name
Not Available
SMILES
Not Available

Pharmacology

Indication

Used in the topical treatment of vulvovaginal candidiasis.

Structured Indications
Not Available
Pharmacodynamics

Candicidin is a polyene antifungal antibiotic produced by a strain of Streptomyces griseus. It is especially effective against Candida albicans (more effective than amphotericin B), and is administered intravaginally in the treatment of vulvovaginal candidiasis.

Mechanism of action

Ergosterol, the principal sterol in the fungal cytoplasmic membrane, is the target site of action of Candicidin. Candicidin binds irreversibly to ergosterol, resulting in disruption of membrane integrity and ultimately cell death. There is some evidence that the binding site in the cell wall may be to fatty acids or fatty acid esters and that this binding capacity must be satisfied before candicidin can bring about its lethal effect by binding to sterol in the cell membrane.

TargetActionsOrganism
AErgosterol
antagonist
Candida albicans
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Various Fungus Species
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AgmatineThe therapeutic efficacy of Candicidin can be increased when used in combination with Agmatine.Experimental, Investigational
AmiodaroneThe therapeutic efficacy of Candicidin can be increased when used in combination with Amiodarone.Approved, Investigational
AmlodipineThe therapeutic efficacy of Candicidin can be increased when used in combination with Amlodipine.Approved
Amphotericin BThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Candicidin.Approved, Investigational
AmrinoneThe therapeutic efficacy of Candicidin can be increased when used in combination with Amrinone.Approved
AranidipineThe therapeutic efficacy of Candicidin can be increased when used in combination with Aranidipine.Approved, Investigational
AtorvastatinThe risk or severity of rhabdomyolysis can be increased when Candicidin is combined with Atorvastatin.Approved
AzelnidipineThe therapeutic efficacy of Candicidin can be increased when used in combination with Azelnidipine.Approved, Investigational
AzimilideThe therapeutic efficacy of Candicidin can be increased when used in combination with Azimilide.Investigational
BarnidipineThe therapeutic efficacy of Candicidin can be increased when used in combination with Barnidipine.Approved
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Candicidin.Investigational
BencyclaneThe therapeutic efficacy of Candicidin can be increased when used in combination with Bencyclane.Experimental
BenidipineThe therapeutic efficacy of Candicidin can be increased when used in combination with Benidipine.Approved, Investigational
BepridilThe therapeutic efficacy of Candicidin can be increased when used in combination with Bepridil.Approved, Withdrawn
BuspironeThe metabolism of Buspirone can be decreased when combined with Candicidin.Approved, Investigational
BusulfanThe serum concentration of Busulfan can be increased when it is combined with Candicidin.Approved, Investigational
CarboxyamidotriazoleThe therapeutic efficacy of Candicidin can be increased when used in combination with Carboxyamidotriazole.Investigational
CaroverineThe therapeutic efficacy of Candicidin can be increased when used in combination with Caroverine.Experimental
CerivastatinThe risk or severity of rhabdomyolysis can be increased when Candicidin is combined with Cerivastatin.Approved, Withdrawn
CilnidipineThe therapeutic efficacy of Candicidin can be increased when used in combination with Cilnidipine.Approved, Investigational
CinnarizineThe therapeutic efficacy of Candicidin can be increased when used in combination with Cinnarizine.Approved, Investigational
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Candicidin.Approved, Investigational, Withdrawn
ClevidipineThe therapeutic efficacy of Candicidin can be increased when used in combination with Clevidipine.Approved, Investigational
CyclandelateThe therapeutic efficacy of Candicidin can be increased when used in combination with Cyclandelate.Approved
CyclosporineThe metabolism of Cyclosporine can be decreased when combined with Candicidin.Approved, Investigational, Vet Approved
DarodipineThe therapeutic efficacy of Candicidin can be increased when used in combination with Darodipine.Experimental
DidanosineDidanosine can cause a decrease in the absorption of Candicidin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DiltiazemThe therapeutic efficacy of Candicidin can be increased when used in combination with Diltiazem.Approved, Investigational
DocetaxelThe metabolism of Docetaxel can be decreased when combined with Candicidin.Approved, Investigational
DofetilideThe serum concentration of Dofetilide can be increased when it is combined with Candicidin.Approved, Investigational
DotarizineThe therapeutic efficacy of Candicidin can be increased when used in combination with Dotarizine.Investigational
EfonidipineThe therapeutic efficacy of Candicidin can be increased when used in combination with Efonidipine.Approved, Investigational
EperisoneThe therapeutic efficacy of Candicidin can be increased when used in combination with Eperisone.Approved, Investigational
EthosuximideThe therapeutic efficacy of Candicidin can be increased when used in combination with Ethosuximide.Approved
EtravirineThe serum concentration of Etravirine can be increased when it is combined with Candicidin.Approved
FelodipineThe therapeutic efficacy of Candicidin can be increased when used in combination with Felodipine.Approved, Investigational
FendilineThe therapeutic efficacy of Candicidin can be increased when used in combination with Fendiline.Withdrawn
FlunarizineThe therapeutic efficacy of Candicidin can be increased when used in combination with Flunarizine.Approved
FluspirileneThe therapeutic efficacy of Candicidin can be increased when used in combination with Fluspirilene.Approved, Investigational
FluvastatinThe risk or severity of rhabdomyolysis can be increased when Candicidin is combined with Fluvastatin.Approved
FosphenytoinThe serum concentration of Candicidin can be decreased when it is combined with Fosphenytoin.Approved, Investigational
GabapentinThe therapeutic efficacy of Candicidin can be increased when used in combination with Gabapentin.Approved, Investigational
GallopamilThe therapeutic efficacy of Candicidin can be increased when used in combination with Gallopamil.Investigational
IsradipineThe therapeutic efficacy of Candicidin can be increased when used in combination with Isradipine.Approved, Investigational
LacidipineThe therapeutic efficacy of Candicidin can be increased when used in combination with Lacidipine.Approved, Investigational
LamotrigineThe therapeutic efficacy of Candicidin can be increased when used in combination with Lamotrigine.Approved, Investigational
LercanidipineThe therapeutic efficacy of Candicidin can be increased when used in combination with Lercanidipine.Approved, Investigational
LevetiracetamThe therapeutic efficacy of Candicidin can be increased when used in combination with Levetiracetam.Approved, Investigational
LidoflazineThe therapeutic efficacy of Candicidin can be increased when used in combination with Lidoflazine.Experimental
LoperamideThe therapeutic efficacy of Candicidin can be increased when used in combination with Loperamide.Approved
LosartanThe metabolism of Losartan can be decreased when combined with Candicidin.Approved
LovastatinThe risk or severity of rhabdomyolysis can be increased when Candicidin is combined with Lovastatin.Approved, Investigational
Magnesium sulfateThe therapeutic efficacy of Candicidin can be increased when used in combination with Magnesium sulfate.Approved, Investigational, Vet Approved
ManidipineThe therapeutic efficacy of Candicidin can be increased when used in combination with Manidipine.Approved, Investigational
MethsuximideThe therapeutic efficacy of Candicidin can be increased when used in combination with Methsuximide.Approved
MevastatinThe risk or severity of rhabdomyolysis can be increased when Candicidin is combined with Mevastatin.Experimental
MibefradilThe therapeutic efficacy of Candicidin can be increased when used in combination with Mibefradil.Investigational, Withdrawn
NaftopidilThe therapeutic efficacy of Candicidin can be increased when used in combination with Naftopidil.Investigational
NicardipineThe therapeutic efficacy of Candicidin can be increased when used in combination with Nicardipine.Approved, Investigational
NifedipineThe therapeutic efficacy of Candicidin can be increased when used in combination with Nifedipine.Approved
NiguldipineThe therapeutic efficacy of Candicidin can be increased when used in combination with Niguldipine.Experimental
NiludipineThe therapeutic efficacy of Candicidin can be increased when used in combination with Niludipine.Experimental
NilvadipineThe therapeutic efficacy of Candicidin can be increased when used in combination with Nilvadipine.Approved, Investigational
NimesulideThe therapeutic efficacy of Candicidin can be increased when used in combination with Nimesulide.Approved, Investigational, Withdrawn
NimodipineThe therapeutic efficacy of Candicidin can be increased when used in combination with Nimodipine.Approved, Investigational
NisoldipineThe therapeutic efficacy of Candicidin can be increased when used in combination with Nisoldipine.Approved
NitrendipineThe therapeutic efficacy of Candicidin can be increased when used in combination with Nitrendipine.Approved, Investigational
OtiloniumThe therapeutic efficacy of Candicidin can be increased when used in combination with Otilonium.Experimental, Investigational
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Candicidin.Approved, Vet Approved
Picosulfuric acidThe therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Candicidin.Approved
PinaveriumThe therapeutic efficacy of Candicidin can be increased when used in combination with Pinaverium.Approved
PitavastatinThe risk or severity of rhabdomyolysis can be increased when Candicidin is combined with Pitavastatin.Approved
PravastatinThe risk or severity of rhabdomyolysis can be increased when Candicidin is combined with Pravastatin.Approved
PrenylamineThe therapeutic efficacy of Candicidin can be increased when used in combination with Prenylamine.Withdrawn
ProgesteroneThe absorption of Progesterone can be decreased when combined with Candicidin.Approved, Vet Approved
QuinidineThe serum concentration of Quinidine can be increased when it is combined with Candicidin.Approved, Investigational
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Candicidin.Approved, Investigational
RifabutinThe serum concentration of Rifabutin can be increased when it is combined with Candicidin.Approved, Investigational
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Candicidin.Approved
RifapentineThe serum concentration of Rifapentine can be increased when it is combined with Candicidin.Approved, Investigational
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Candicidin.Approved, Investigational
RosuvastatinThe risk or severity of rhabdomyolysis can be increased when Candicidin is combined with Rosuvastatin.Approved
SeletracetamThe therapeutic efficacy of Candicidin can be increased when used in combination with Seletracetam.Investigational
SimvastatinThe risk or severity of rhabdomyolysis can be increased when Candicidin is combined with Simvastatin.Approved
SolifenacinThe metabolism of Solifenacin can be decreased when combined with Candicidin.Approved
SucralfateSucralfate can cause a decrease in the absorption of Candicidin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SunitinibThe metabolism of Sunitinib can be decreased when combined with Candicidin.Approved, Investigational
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Candicidin.Approved, Investigational
TerodilineThe therapeutic efficacy of Candicidin can be increased when used in combination with Terodiline.Experimental
TetrahydropalmatineThe therapeutic efficacy of Candicidin can be increased when used in combination with Tetrahydropalmatine.Investigational
Tolfenamic AcidThe therapeutic efficacy of Candicidin can be increased when used in combination with Tolfenamic Acid.Approved, Investigational
TranilastThe therapeutic efficacy of Candicidin can be increased when used in combination with Tranilast.Approved, Investigational
TrimebutineThe therapeutic efficacy of Candicidin can be increased when used in combination with Trimebutine.Approved
TrimethadioneThe therapeutic efficacy of Candicidin can be increased when used in combination with Trimethadione.Approved
VerapamilThe therapeutic efficacy of Candicidin can be increased when used in combination with Verapamil.Approved
VinpocetineThe therapeutic efficacy of Candicidin can be increased when used in combination with Vinpocetine.Investigational
WIN 55212-2The therapeutic efficacy of Candicidin can be increased when used in combination with WIN 55212-2.Experimental
ZiconotideThe therapeutic efficacy of Candicidin can be increased when used in combination with Ziconotide.Approved
ZolpidemThe serum concentration of Zolpidem can be increased when it is combined with Candicidin.Approved
ZonisamideThe therapeutic efficacy of Candicidin can be increased when used in combination with Zonisamide.Approved, Investigational
Food Interactions
Not Available

References

Synthesis Reference

Siminoff, P.; U.S. Patent 2,872,373; February 3,1959; assigned to S.B. Penick & Company, Inc. Waksman, S.A. and Lechevalier, H.A.; U.S. Patent 2,992,162; July 11,1961; assigned to Rutgers Research and Educational Foundation.

General References
Not Available
External Links
Human Metabolome Database
HMDB15283
KEGG Drug
D03347
KEGG Compound
C06690
PubChem Substance
46504812
ChemSpider
10128184
ChEBI
354984
ChEMBL
CHEMBL1200647
Therapeutic Targets Database
DAP001325
PharmGKB
PA164754911
Wikipedia
Candicidin
ATC Codes
G01AA04 — Candicidin

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
logP1.7Not Available
Predicted Properties
Not Available
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.9509
Blood Brain Barrier-0.9398
Caco-2 permeable-0.7585
P-glycoprotein substrateSubstrate0.8004
P-glycoprotein inhibitor INon-inhibitor0.5359
P-glycoprotein inhibitor IIInhibitor0.6783
Renal organic cation transporterNon-inhibitor0.952
CYP450 2C9 substrateNon-substrate0.7747
CYP450 2D6 substrateNon-substrate0.8665
CYP450 3A4 substrateSubstrate0.5161
CYP450 1A2 substrateNon-inhibitor0.8668
CYP450 2C9 inhibitorNon-inhibitor0.9212
CYP450 2D6 inhibitorNon-inhibitor0.9092
CYP450 2C19 inhibitorNon-inhibitor0.8723
CYP450 3A4 inhibitorNon-inhibitor0.8064
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9525
Ames testNon AMES toxic0.8306
CarcinogenicityNon-carcinogens0.9559
BiodegradationNot ready biodegradable0.9959
Rat acute toxicity2.5750 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9748
hERG inhibition (predictor II)Non-inhibitor0.7767
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Targets

1. Ergosterol
Kind
Small molecule
Organism
Candida albicans
Pharmacological action
Yes
Actions
Antagonist
References
  1. Hammond SM, Kliger BN: Mode of action of the polyene antibiotic candicidin: binding factors in the wall of Candida albicans. Antimicrob Agents Chemother. 1976 Apr;9(4):561-8. [PubMed:773298]
  2. Brajtburg J, Elberg S, Kobayashi GS, Medoff G: Effects of serum lipoproteins on damage to erythrocytes and Candida albicans cells by polyene antibiotics. J Infect Dis. 1986 Mar;153(3):623-6. [PubMed:3512734]
  3. Borgers M: Mechanism of action of antifungal drugs, with special reference to the imidazole derivatives. Rev Infect Dis. 1980 Jul-Aug;2(4):520-34. [PubMed:7003674]

Drug created on June 13, 2005 07:24 / Updated on March 02, 2018 02:08